273 related articles for article (PubMed ID: 31447858)
1. Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies.
Marrella A; Dondero A; Aiello M; Casu B; Olive D; Regis S; Bottino C; Pende D; Meazza R; Caluori G; Castriconi R; Scaglione S
Front Immunol; 2019; 10():1876. PubMed ID: 31447858
[TBL] [Abstract][Full Text] [Related]
2. Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages.
Bellora F; Dondero A; Corrias MV; Casu B; Regis S; Caliendo F; Moretta A; Cazzola M; Elena C; Vinti L; Locatelli F; Bottino C; Castriconi R
J Immunol; 2017 Aug; 199(4):1516-1525. PubMed ID: 28701512
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Veneziani I; Brandetti E; Ognibene M; Pezzolo A; Pistoia V; Cifaldi L
J Immunol Res; 2018; 2018():4972410. PubMed ID: 29805983
[TBL] [Abstract][Full Text] [Related]
4. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.
Tarek N; Le Luduec JB; Gallagher MM; Zheng J; Venstrom JM; Chamberlain E; Modak S; Heller G; Dupont B; Cheung NK; Hsu KC
J Clin Invest; 2012 Sep; 122(9):3260-70. PubMed ID: 22863621
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.
Bottino C; Dondero A; Bellora F; Moretta L; Locatelli F; Pistoia V; Moretta A; Castriconi R
Front Immunol; 2014; 5():56. PubMed ID: 24575100
[TBL] [Abstract][Full Text] [Related]
6. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.
Pesce S; Greppi M; Grossi F; Del Zotto G; Moretta L; Sivori S; Genova C; Marcenaro E
Front Immunol; 2019; 10():1242. PubMed ID: 31214193
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.
Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116
[TBL] [Abstract][Full Text] [Related]
9. The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma.
Pathania AS; Chava H; Chaturvedi NK; Chava S; Byrareddy SN; Coulter DW; Challagundla KB
Cell Death Dis; 2024 Jun; 15(6):428. PubMed ID: 38890285
[TBL] [Abstract][Full Text] [Related]
10. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants.
Dondero A; Morini M; Cangelosi D; Mazzocco K; Serra M; Spaggiari GM; Rotta G; Tondo A; Locatelli F; Castellano A; Scuderi F; Sementa AR; Eva A; Conte M; Garaventa A; Bottino C; Castriconi R
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795387
[TBL] [Abstract][Full Text] [Related]
12. NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.
Shoae-Hassani A; Hamidieh AA; Behfar M; Mohseni R; Mortazavi-Tabatabaei SA; Asgharzadeh S
J Immunother; 2017 Sep; 40(7):265-276. PubMed ID: 28622272
[TBL] [Abstract][Full Text] [Related]
13. Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells.
Cordeau M; Belounis A; Lelaidier M; Cordeiro P; Sartelet H; Herblot S; Duval M
PLoS One; 2016; 11(10):e0164401. PubMed ID: 27716850
[TBL] [Abstract][Full Text] [Related]
14. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.
Forlenza CJ; Boudreau JE; Zheng J; Le Luduec JB; Chamberlain E; Heller G; Cheung NK; Hsu KC
J Clin Oncol; 2016 Jul; 34(21):2443-51. PubMed ID: 27069083
[TBL] [Abstract][Full Text] [Related]
15. Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma in vitro and in vivo.
Pérez-Martínez A; Valentín J; Fernández L; Hernández-Jiménez E; López-Collazo E; Zerbes P; Schwörer E; Nuñéz F; Martín IG; Sallis H; Díaz MÁ; Handgretinger R; Pfeiffer MM
Cytotherapy; 2015 May; 17(5):601-12. PubMed ID: 25541298
[TBL] [Abstract][Full Text] [Related]
16. Bioengineering a novel 3D in vitro model of gastric mucosa for stomach permeability studies.
Lourenço BN; Dos Santos T; Oliveira C; Barrias CC; Granja PL
Acta Biomater; 2018 Dec; 82():68-78. PubMed ID: 30308252
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-kB p65 Subunit-Induced Expression of FAS and PVR, the Loss of Which Is Associated with Poor Patient Outcome.
Brandetti E; Focaccetti C; Pezzolo A; Ognibene M; Folgiero V; Cotugno N; Benvenuto M; Palma P; Manzari V; Rossi P; Fruci D; Bei R; Cifaldi L
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503178
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance.
Dondero A; Pastorino F; Della Chiesa M; Corrias MV; Morandi F; Pistoia V; Olive D; Bellora F; Locatelli F; Castellano A; Moretta L; Moretta A; Bottino C; Castriconi R
Oncoimmunology; 2016; 5(1):e1064578. PubMed ID: 26942080
[TBL] [Abstract][Full Text] [Related]
19. Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells.
Pelizzo G; Veschi V; Mantelli M; Croce S; Di Benedetto V; D'Angelo P; Maltese A; Catenacci L; Apuzzo T; Scavo E; Moretta A; Todaro M; Stassi G; Avanzini MA; Calcaterra V
BMC Cancer; 2018 Nov; 18(1):1176. PubMed ID: 30482160
[TBL] [Abstract][Full Text] [Related]
20. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.
Brandetti E; Veneziani I; Melaiu O; Pezzolo A; Castellano A; Boldrini R; Ferretti E; Fruci D; Moretta L; Pistoia V; Locatelli F; Cifaldi L
Oncoimmunology; 2017; 6(6):e1316439. PubMed ID: 28680748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
